Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Merck Pepcid AC Orally Disintegrating Tablets In The Works

This article was originally published in The Tan Sheet

Executive Summary

J&J/Merck is looking to extend its category-leading Pepcid AC franchise with an orally disintegrating dosage form developed by Yamanouchi Pharma Technologies.
Advertisement

Related Content

H2s
H2s
Glaxo Zantac 75 Divestiture To W-L Required By FTC
Generic Famotidine Launch Delayed By Pepcid AC Pediatric Exclusivity
J&J/Merck Pepcid Complete Combines H2 Antagonist/Antacid Ingredients
Aquafresh Gum, Lozenges Carry "For Oral Care - Anytime, Anywhere" Tagline
Benadryl Children's Allergy/Cold Line Adding Fastmelt Quick-Dissolve Form
J&J/Merck Pepcid AC Chewable Ads Send "Unintended Message" - NAD
Pepcid AC gelcaps
Pepcid AC gelcaps

Topics

Advertisement
UsernamePublicRestriction

Register

PS091507

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel